Analyst Reco. BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
81.83 ^USD	-0.91%		-1.80%	-15.13%

May. 06	Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing	MT
May. 04	Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing	May. 06	MT
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	May. 03
Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating	Apr. 25	MT
Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating	Apr. 25	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	Apr. 15	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	Apr. 01	MT
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside	Feb. 23	MT
BofA Securities Cuts BioMarin Pharmaceutical Price Target to $150 From $170, Maintains Buy Rating	Jan. 26	MT
If you didn’t have enough signs, here’s more	Nov. 15
ANALYST RECOMMENDATIONS : Datadog, Fair Isaac, HSBC, Home Depot, Wise...	Nov. 15
BMO Capital Adjusts Price Target on BioMarin Pharmaceutical to $100 From $102, Keeps Outperform Rating	Nov. 03	MT
UBS Trims BioMarin Pharmaceutical Price Target to $119 From $120, Maintains Buy Rating	Nov. 02	MT
Barclays Cuts BioMarin Pharmaceutical's Price Target to $111 From $125, Overweight Rating Maintained	Nov. 02	MT
Cantor Fitzgerald Adjusts Price Target on BioMarin Pharmaceutical to $100 From $120, Maintains Overweight Rating	Nov. 02	MT
ANALYST RECOMMENDATIONS : Airbnb, Intel, CVS, Caterpillar, Qualcomm...	Nov. 02
Morgan Stanley Cuts Price Target on BioMarin Pharmaceutical to $117 From $125, Keeps Overweight Rating	Nov. 02	MT
Bernstein Upgrades BioMarin to Market Perform From Underperform, Price Target is $82	23-10-23	MT
ANALYST RECOMMENDATIONS : Amazon, Procter & Gamble, Salesforce, Unilever, Walgreens Boots...	23-10-23
ANALYST RECOMMENDATIONS : Amex, Biogen, Dollar General, Fortinet, Whitbread...	23-10-13
UBS Initiates Coverage on BioMarin Pharmaceutical With Buy Rating, $120 Price Target	23-09-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Analyst Reco.

Filters